Postanesthetic Recovery

  • Lois L. Bready
Part of the Developments in Critical Care Medicine and Anesthesiology book series (DCCA, volume 14)

Abstract

The clinical considerations that are important in selection and implementation of the induction and maintenance of anesthesia in the patient undergoing renal transplantation are generally still present at the time of recovery from anesthesia. This chapter will deal with clinical problems frequently encountered during the first 24 hours after renal transplantation. This is an arbitrary distinction but facilitates discussion of immediate postoperative and postanesthetic events. In “Anesthesia Related Morbidity” (chapter 13), events are covered which are likely to become manifest longer than 24 hours after renal transplantation.

Keywords

Lidocaine Verapamil Hyperglycemia Midazolam Nifedipine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Drayer DE: Active drug metabolites in renal failure. Am J Med 62:486, 1977.PubMedCrossRefGoogle Scholar
  2. 2.
    Maher JF: Pharmacokinetics in patients with renal failure. Clin Nephrol 21:39, 1984.PubMedGoogle Scholar
  3. 3.
    Grodstein G, Harrison A, Robert C, et al.: Impaired gastric emptying in hemodialysis patients (Abstract). Kidney Int 16:952A, 1979.Google Scholar
  4. 4.
    Weil R, Schroter GPJ, West JC, et al.: A fourteen year experience with kidney transplantation. World J of Surg 1:145, 1977.CrossRefGoogle Scholar
  5. 5.
    Murray JE, Tilney NL, Wilson RE: Renal transplantation: a twenty-five year experience. Ann Surg 184:565, 1976.PubMedCrossRefGoogle Scholar
  6. 6.
    Matas AJ, Simmons RL, Buselmeier TJ, et al.: The fate of patients surviving three years after renal transplantation. Surg 80:390, 1976.Google Scholar
  7. 7.
    Ivey GL, Richie RE, Niblack GD, et al.: Renal transplantation: a twenty year experience in a Veteran’s Administration Medical Center. Arch Surg 120:1021, 1985.PubMedGoogle Scholar
  8. 8.
    Aldrete JA, Daniel W, O’Higgins JW, et al.: Analysis of anesthetic-related morbidity in human recipients of renal homografts. Anesth Analg 50:321, 1971.PubMedGoogle Scholar
  9. 9.
    Miller RD, Cullen DJ: Renal failure and postoperative respiratory failure: recurarization? Br J Anaesth 48:253, 1976.PubMedCrossRefGoogle Scholar
  10. 10.
    Sirotzky L, Lewis EJ: Anesthesia related muscle paralysis in renal failure. Clin Nephrol 10:38, 1978.PubMedGoogle Scholar
  11. 11.
    Abrams RE, Hornbein TF: Inability to reverse pancuronium blockade in a patient with renal failure and hepatic disease. Anesthesiology 42:362, 1975.PubMedCrossRefGoogle Scholar
  12. 12.
    Bradley JP, Marslen AR, O’Connor JP: Prolonged neuromuscular blockade after renal transplantation. Anaesth Intensive Care 13:196, 1985.PubMedGoogle Scholar
  13. 13.
    Rouse JM, Galley RLA, Bevan DR: Prolonged curarisation following renal transplantation. Anaesthesia 32:247, 1977.PubMedCrossRefGoogle Scholar
  14. 14.
    Ramsey FM, Lebowitz PW, Savarese JJ, et al.: Clinial characteristics of long-term succiny- lcholine neuromuscular blockade during balanced anesthesia. Anesth Analg 59:110, 1980.PubMedGoogle Scholar
  15. 15.
    Donati F, Bevan DR: Antagonism of phase II succinylcholine block by neostigmine. Anesth Analg 64:773, 1985.PubMedCrossRefGoogle Scholar
  16. 16.
    Ryan DW: Preoperative serum cholinesterase concentration in chronic renal failure. Br J Anaesth 49:945, 1977.PubMedCrossRefGoogle Scholar
  17. 17.
    Bishop MJ, Hornbein TF: Prolonged effect of succinylcholine after neostigmine and pyridostigmine administration in patients with renal failure. Anesthesiology 58:384, 1983.PubMedCrossRefGoogle Scholar
  18. 18.
    McLeod K, Watson MJ, Rawlings MD: Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 48:341, 1976.PubMedCrossRefGoogle Scholar
  19. 19.
    Miller RD, Matteo RS, Benet LZ, et al.: The pharmacokinetics of d-tubocurarine in patients with and without renal failure. J Pharm Exp Ther 202:1, 1977.Google Scholar
  20. 20.
    Cohen EN, Brewer HW, Smith D: The metabolism and elimination of d-tubocurarine -H3. Anesthesiology 28:309, 1967.PubMedCrossRefGoogle Scholar
  21. 21.
    Brooks DK, Feldman SA: Metabolic acidosis: a new approach to “neostigmine resistant curarisation.” Anaesthesia 17:161, 1962.PubMedCrossRefGoogle Scholar
  22. 22.
    Riordan DD, Gilbertson AA: Prolonged curarization in a patient with renal failure. Br J Anaesth 43:506, 1971.PubMedCrossRefGoogle Scholar
  23. 23.
    Gibaldi M, Levy G, Hayton WL: Tubocurarine and renal failure. Br J Anaesth 44:163, 1972.PubMedCrossRefGoogle Scholar
  24. 24.
    Somogyi A A, Shanks CA, Triggs EJ: The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide. Eur J Clin Pharm 12:23, 1977.CrossRefGoogle Scholar
  25. 25.
    Miller RD, Stevens WC, Way WL: The effect of renal failure and hyperkalemia on the duration of pancuronium neuromuscular blockade in man. Anesth Analg 52:661, 1973.PubMedGoogle Scholar
  26. 26.
    Bevan DR, Archer D, Donati F, et al.: Antagonism of pancuronium in renal failure: no re- curarization. Br J Anaesth 54:63, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Geha DG, Blitt CD, Moon BJ: Prolonged neuromuscular blockade with pancuronium in the presence of acute renal failure: a case report. Anesth Analg 55:343, 1976.PubMedCrossRefGoogle Scholar
  28. 28.
    Meistelman C, Lienhart A, Leveque C, et al.: Pharmacology of vecuronium in patients with end-stage renal failure. Anesthesiology 59:A293, 1983.Google Scholar
  29. 29.
    Bencini AF, Scaf AHJ, Sohn YJ, et al.: Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesth Analg 65:245, 1986.PubMedCrossRefGoogle Scholar
  30. 30.
    Bevan DR, Donati F, Gyasi H, et al.: Vecuronium in renal failure. Can Anaesth So 31:491, 1984.CrossRefGoogle Scholar
  31. 31.
    Fahey MR, Morris RB, Miller RD, et al.: Pharmacokinetics of Org NC45 (Norcuron) in patients with and without renal failure. Br J Anaesth 53:1049, 1981.PubMedCrossRefGoogle Scholar
  32. 32.
    Hunter JM, Jones RS, Utting EE: Comparison of vecuronium, atracurium and tubocurarine in normal patients and patients with no renal function. Br J Anaesth 56:941, 1984.PubMedCrossRefGoogle Scholar
  33. 33.
    Funk FJ, Crul JF, Vander Pol FM: Effects of changes in acid-base balance in neuromuscular blockade produced by ORG-NC45. Acta Anaesth Scand 24:119, 1980.PubMedCrossRefGoogle Scholar
  34. 34.
    Gencarelli PJ, Swen J, Koot HWJ, et al.: The effects of hypercarbia and hypocarbia on pancuronium and vecuronium neuromuscular blockade in anesthetized humans. Anesthesiology 59:376, 1983.PubMedCrossRefGoogle Scholar
  35. 35.
    Foldes FF, Bencini A, Newton D: Influence of halothane and enflurane on the neuromuscular blocking effects of Org NC45 in man. Br J Anaesth 52:64S, 1980.Google Scholar
  36. 36.
    Rupp SM, Miller RD, Gencarelli PJ: Vecuronium induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans. Anesthesiology 60:102, 1984.PubMedCrossRefGoogle Scholar
  37. 37.
    Kreig N, Rutten JMJ, Crul JF, et al.: Preliminary review of the interactions of Org NC45 with anaesthetics and antibiotics in animals. Br J Anaesth 52:33S, 1980.Google Scholar
  38. 38.
    Hunter JM, Jones RS, Utting JE: Use of atracurium in patients with no renal function. Br J Anaesth 54:1251, 1982.PubMedCrossRefGoogle Scholar
  39. 39.
    Fahey MR, Rupp SM, Fisher DM, et al.: Pharmacokinetics and pharmacodynamics of atracurium in normal and renal failure patients. Anesthesiology 59:A263, 1983.Google Scholar
  40. 40.
    Fahey MR, Rupp SM, Fisher DM, et al.: The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61:699, 1984.PubMedCrossRefGoogle Scholar
  41. 41.
    Hughes R, Chappie DJ: The pharmacology of atracurium: a new competitive neuromuscular blocking agent. Br J Anaesth 53:31, 1981.PubMedCrossRefGoogle Scholar
  42. 42.
    Cronnelly R, Stanski DR, Miller RD, et al.: Renal function in the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology 51:222, 1979.PubMedCrossRefGoogle Scholar
  43. 43.
    Stanski DR, Miller RD, Sheiner LB. Renal function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology 51:222, 1979.PubMedCrossRefGoogle Scholar
  44. 44.
    Cronnelly R, Stanski DR, Miller RD, et al.: Pyridostigmine kinetics with and without renal function. Clin Pharm Therap 28:78, 1980.PubMedCrossRefGoogle Scholar
  45. 45.
    Morris RB, Cronnelly R, Miller RD, et al.: Pharmacokinetics of edrophonium in anephric and renal transplant patients. Br J Anaesth 53:1311, 1981.PubMedCrossRefGoogle Scholar
  46. 46.
    Don HF, Dieppa RA, Taylor P: Narcotic analgesics in anuric patients. Anesthesiology 42:745, 1975.PubMedCrossRefGoogle Scholar
  47. 47.
    Aitkenhead AR, Vater M, Achola K, et al.: Pharmacokinetics of single dose IV morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth 56:813, 1984.PubMedCrossRefGoogle Scholar
  48. 48.
    Moore A, Sear J, Baldwin D, et al.: Morphine kinetics during and after renal transplantation. Clin Pharm Therap 35:641, 1984.PubMedCrossRefGoogle Scholar
  49. 49.
    Sear J, Moore A, Hunniset A, et al.: Morphine kinetics and kidney transplantation: morphine removal is influenced by renal ischemia. Anesth Analg 64:1065, 1985.PubMedCrossRefGoogle Scholar
  50. 50.
    Casthely PA, Villaneuva R: Level of consciousness after cadaveric kidney trasnsplant under halothane anesthesia. Can Anaesth So 30:587, 1983.CrossRefGoogle Scholar
  51. 51.
    Wiggum DC, Cork RC, Weldon ST, et al.: Postoperative respiratory depression and elevated sufentanil levels in a patient with chronic renal failure. Anesthesiology 63:708, 1985.PubMedCrossRefGoogle Scholar
  52. 52.
    Lehmann CR, Heironimus JD, Collins CB, et al.: Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Clin Pharm Therap 37:284, 1985.PubMedCrossRefGoogle Scholar
  53. 53.
    Gifford RRM, Schmidtke JR, Ferguson RM: Cimetidine modulation of lymphocytes from renal allograft recipients. Transpl Proc 13:663, 1981.Google Scholar
  54. 54.
    Niessen GJCM, Obertop H, Kort WJ: Cimetidine and renal allograft survival. Surg 91:116, 1982.Google Scholar
  55. 55.
    Weir PHC, Chung FF: Anaesthesia for patients with chronic renal disease. Can Anesth Soc J 31:468, 1984.CrossRefGoogle Scholar
  56. 56.
    Ghoneim MM, Pandya H: Plasma protein binding of thiopental in patients with impaired renal or hepatic function. Anesthesiology 42:545, 1975.PubMedCrossRefGoogle Scholar
  57. 57.
    Dundee JW, Richards RK: Effect of azotemia upon the action of intravenous barbituate anesthesia. Anesthesiology 15:333, 1954.PubMedCrossRefGoogle Scholar
  58. 58.
    Burch PG, Stanski DR: Pharmacokinetics of thiopental in renal failure. Anesthesiology 55:A176, 1981.CrossRefGoogle Scholar
  59. 59.
    Bennett WM, Muther RS, Parker RA, et al.: Drug therapy in renal failure: Dosing guidelines for adults. Ann Intern Med 93:62 and 286, 1980.PubMedGoogle Scholar
  60. 60.
    Vinik R, Reves JG, Nixon D, et al.: Midazolam induction and emergence in renal failure patients. Anesthesiology 55:A262, 1981.Google Scholar
  61. 61.
    Miller RD, Sohn YJ, Matteo RS: Enhancement of d-tubocurarine neuromuscular blockade by diuretics in man. Anesthesiology 45:442, 1976.PubMedCrossRefGoogle Scholar
  62. 62.
    Tilstone WJ, Fine A: Furosemide kinetics in renal failure. Clin Pharm Therap 23:644, 1978.PubMedGoogle Scholar
  63. 63.
    Berry AJ, Peterson ML: Hyponatremia after mannitol administration in the presence of renal failure. Anesth Analg 60:165, 1981.PubMedCrossRefGoogle Scholar
  64. 64.
    Borges HF, Hocks J, Kjellstrand CM: Mannitol intoxication in patients with renal failure. Arch Intern Med 142:63, 1982.PubMedCrossRefGoogle Scholar
  65. 65.
    Charters P: Mannitol, osmolality and steroids during renal transplantation. Anaesthesia 38:327, 1983.PubMedCrossRefGoogle Scholar
  66. 66.
    Rauscher LA, Hurst JM, Collins GM: Nitroprusside toxicity in a renal transplant patient. Anesthesiology 49:428, 1978.PubMedCrossRefGoogle Scholar
  67. 67.
    Collinsworth KA, Strong JM, Atkinson AJ, Jr., et al.: Pharmacokinetics and metabolism of lidocaine in patients with renal failure. Clin Pharm Therap 18:59, 1975.PubMedGoogle Scholar
  68. 68.
    Lowenthal DT: Pharmacokinetics of propranolol, quinidine, procainamide and lidocaine in chronic renal disease. Am J Med 62:532, 1977.PubMedCrossRefGoogle Scholar
  69. 69.
    Bianchetti G, Graziana G, Brancaccio D, et al.: Pharmacokinetics and effects of propranolol in terminal uremic patients and in patients undergoing regular dialysis treatment. Clin Pharm 1:373, 1976.CrossRefGoogle Scholar
  70. 70.
    Bikhazi GB, Leung I, Foldes FF: Ca-channel blockers increase potency of neuromuscular blocking agents in vivo. Anesthesiology 59:A269, 1983.Google Scholar
  71. 71.
    Aldrete JA, Clapp HW, Starzl TE: Body temperature changes during organ transplantation. Anesth Analg 49:384, 1970.PubMedGoogle Scholar
  72. 72.
    Najarian JS, Simmons RL, Condie RM, et al.: Seven years’ experience with ALG for renal transplantation from cadaver donors. Ann Surg 184:352, 1976.PubMedCrossRefGoogle Scholar
  73. 73.
    Lissoos I, Goldberg B, Vanblerk JP, et al.: Surgical procedures on patients in end-stage renal failure. Br J Urol 45:359, 1973.PubMedCrossRefGoogle Scholar
  74. 74.
    Brenowitz JB, Williams CD, Edwards. WS: Major surgery in patients with chronic renal failure. Am J Surg 134:765, 1977.PubMedCrossRefGoogle Scholar
  75. 75.
    Carlier M, Squifflet JP, Pirson Y, et al.: Maximal hydration during anesthesia increases pulmonary artery pressures and improves early function of human renal transplants. Transplantation 34:201, 1982.PubMedCrossRefGoogle Scholar
  76. 76.
    Marsland AR, Bradley JP: Anesthesia for renal transplantation: five years’ experience. Anesth Inten Care 11:337, 1983.Google Scholar
  77. 77.
    Hampers CL, Bailey GL, Hager EB, et al.: Major surgery in patients on maintenance hemodialysis. Am J Surg 115:747, 1968.PubMedCrossRefGoogle Scholar
  78. 78.
    Friedman M, Libert R, Michaelson ED: Unilateral pulmonary edema after renal transplantation. N Engl J Med 293:343, 1975.PubMedCrossRefGoogle Scholar
  79. 79.
    Adrougue HJ, Madias NE: Changes in plasma potassium concentration during acute acid—base disturbances. Am J of Med 71:456, 1981.CrossRefGoogle Scholar
  80. 80.
    Charters P: Renal transplantation in diabetes mellitus. Anaesthesia 35:199, 1981.CrossRefGoogle Scholar
  81. 81.
    Hansen DD, Fernandes A, Skovsted P, et al.: Cyclopropane anesthesia for renal transplantation: report of 100 cases. Br J Anaesth 44:584, 1972.PubMedCrossRefGoogle Scholar
  82. 82.
    D’Elia JA, Kaldany A, Miller DG, et al.: Moxalactam, bleeding, and renal insufficiency. JAMA 249:1565, 1983.PubMedCrossRefGoogle Scholar
  83. 83.
    Carvalho ACA: Bleeding in uremia — a clinical challenge. N Engl J Med 308:38, 1983.PubMedCrossRefGoogle Scholar
  84. 84.
    Janson PA, Jubelirer SJ, Weinstein J, et al.: Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303:1318, 1980.PubMedCrossRefGoogle Scholar
  85. 85.
    Mannucci PM, Renuzzi G, Pusineri F, et al.: Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8, 1983.PubMedCrossRefGoogle Scholar
  86. 86.
    Fernandez F, Goudable C, Sie P, et al.: Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 59:139, 1985.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • Lois L. Bready

There are no affiliations available

Personalised recommendations